A
Alchemab Therapeutics
Develops drugs by identifying naturally protective patient antibodies using three complementary processes and advanced technologies
About Alchemab Therapeutics
Alchemab Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the development of antibody therapeutics for difficult-to-treat diseases. The company's unique approach involves studying the immune systems of resilient individuals, such as long-term cancer survivors, to understand how they resist or overcome disease.
Read full description
The company's business model is centered around the use of adaptive immunity, which is the body's ability to recognize and defend itself against specific infectious agents or diseases. Alchemab uses advanced scientific techniques and deep learning algorithms to identify and replicate the antibodies present in these resilient individuals. These antibodies are then used to create therapeutics that can potentially treat a wide range of diseases.
Alchemab's clients are primarily in the healthcare sector, including hospitals, clinics, and other medical institutions that treat patients with hard-to-treat diseases. The company generates revenue by developing and selling these novel antibody therapeutics.
In summary, Alchemab is a pioneering biotech company that uses innovative techniques to develop new treatments for hard-to-treat diseases. By harnessing the power of the immune system and using advanced technology, the company is at the forefront of the next generation of antibody therapeutics.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- London, United Kingdom
- Employees
- 71
- Open positions
- None listed
- Dealroom signal
- 92.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, AI Drug Discovery, Woman Founder, Techbio Drug Discovery, DT and LS, UKis Digital and technologies
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Alchemab Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2025 | $32M | $410M | SV Health Investors · Eli Lilly · Lilly · DCVC Bio | ↗ |
| GRANTOther financing | Jun 2024 | $595K | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Alchemab Therapeutics is 4.6K monthly website visits, up 12.2% over the last three months. Alchemab Therapeutics's team grew 18.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
SV Health Investors
DCVC
Michael J. Fox Foundation for Parkinson's Research
Series A8 investors entered at this stage
RA Capital Management
Lightstone Ventures
DHVC (Danhua Capital)
Dementia Discovery Fund
Ono Venture Investment
Eli Lilly
Lilly
DCVC Bio
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alchemab Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alchemab Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.